Where did Brazilians get their diabetes drugs during the COVID-19 pandemic? DIABETESvid results
10.15343/0104-7809.202246392400I
DOI:
https://doi.org/10.15343/0104-7809.202246392400PKeywords:
COVID-19, Drug Utilization, Diabetes Mellitus, Type 1. Diabetes Mellitus, Type 2. Health Services AccessibilityAbstract
Access to diabetes medications is critical to disease control. However, social distancing in the COVID-19 pandemic may have limited the provision of medicines and supplies. Thus, the objective of this study was to analyze the sources of obtaining diabetes drugs in the COVID-19 pandemic in Brazil. The data came from the DIABETESvid survey, and this analysis considered a convenience sample of 1608 participants who responded to the questionnaire published on social media of scientific societies related to diabetes. This is a cross-sectional study, conducted in the form of a web survey, from September 1 to October 19, 2020. The outcome analyzed was the sources for obtaining diabetes drugs categorized in pharmacies of the "Sistema Único de Saúde", pharmacies of the “Aqui tem Farmácia Popular” program, as well as private pharmacies and drugstores and other sources. Most participants self-reported a diagnosis of type 1 diabetes mellitus (49.8%), used insulin (61.9%), and had a private health plan (68.7%). Private pharmacies and drugstores and other sources were the main places where medicines for diabetes were supplied (47.5%). Participants residing in the Midwest region of the country had a lower frequency of supply in pharmacies in the “Aqui tem Farmácia Popular” program (0.57; 95%CI 0.36-0.92). In the studied sample, there was a higher frequency of supply of diabetes drugs in private pharmacies and drugstores and other sources with a reduction in frequency in public pharmacies during the COVID-19 pandemic in Brazil.
Downloads
References
2. Barone MTU, Ngongo B, Harnik SB, Oliveira LX, Végh D, de Luca PV, Pedrosa HC, Giraudo F, Cardona-Hernandez R, Chaudhury N, Menna-Barreto L. COVID-19 associated with diabetes and other noncommunicable diseases led to a global health crisis. Diabetes Res Clin Pract. 2021; 171:108587. https://doi.org/10.1016/j.diabres.2020.108587
3. Wu ZH, Tang Y, Cheng Q. Diabetes increases the mortality of patients with COVID-19: a meta-analysis. Acta Diabetol. 2021; 58(2):139-144. https://doi.org/10.1007/s00592-020-01546-0
4. Palaiodimos L, Chamorro-Pareja N, Karamanis D, Li W, Zavras PD, Chang KM, Mathias P, Kokkinidis DG. Diabetes is associated with increased risk for in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis comprising 18,506 patients. Hormones (Athens). 2021; 20(2):305-314. https://doi.org/10.1007/s42000-020-00246-2
5. Wicaksana AL, Hertanti NS, Ferdiana A, Pramono RB. Diabetes management and specific considerations for patients with diabetes during coronavirus diseases pandemic: A scoping review. Diabetes Metab Syndr. 2020;14(5):1109-1120. https://doi. org/10.1016/j.dsx.2020.06.070
6. Karatas S, Yesim T, Beysel S. Impact of lockdown COVID-19 on metabolic control in type 2 diabetes mellitus and healthy people. Prim Care Diabetes. 2021; 15(3):424-427. https://doi.org/10.1016/j.pcd.2021.01.003
7. Gupta SK, Lakshmi PVM, Kaur M, Rastogi A. Role of self-care in COVID-19 pandemic for people living with comorbidities of diabetes and hypertension. J Family Med Prim Care. 2020; 30;9(11):5495-5501. https://doi.org/10.4103/jfmpc.jfmpc_1684_20
8. Brasil. Governo Federal. Lei nº 11.347 de 27 de setembro de 2006: Distribuição gratuita de medicamentos e materiais necessários à sua aplicação e à monitoração da glicemia capilar aos portadores de diabetes. Brasília: Diário Oficial da União; 2006. Seção 1, p. 1.
9. Francisco PMSB, Rodrigues PS, Costa KS, Tavares NUL, Tierling VL, Barros MBDA et al. Prevalência de diabetes em adultos e idosos, uso de medicamentos e fontes de obtenção: uma análise comparativa de 2012 e 2016. Rev Bras Epidemio. 2019; 22: E190061. https://doi.org/10.1590/1980-549720190061
10. Departamento de Assistência Farmacêutica e Insumos Estratégicos da Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde DAF/SCTIE/MS (Brasil). Nota técnica 134/2020, de 18 de março de 2020. Alteração em caráter excepcional e temporária, no âmbito do Programa Farmácia Popular do Brasil (PFPB) - "Aqui Tem Farmácia Popular" COVID-19. Ministério da Saúde. <https://www.gov.br/saude/pt-br/coronavirus/publicacoes-tecnicas/notas-tecnicas/nota-tecnica-134-2020-farmaciapopular.pdf/view>
11. Cabral ERM, Bonfada D, Melo MC, Cesar ID, Oliveira REM, Bastos TF et al. Contributions and challenges of the Primary Health Care across the pandemic COVID-19. InterAm J Med Health. 2020;30:1-12. https://doi.org/10.31005/iajmh.v3i0.87
12. Oliveira REM, Almeida-Pititto B, Binhardi BA, Barbosa-Junior F, Franco LJ, Melo KFS et al. DIABETESvid: Web survey methods for diabetes self-care and resiliencein the COVID-19 pandemic in Brazil. Diabetes Epidemiology and Management. 2021;2:1000152. https://doi.org/10.1016/j.deman.2021.100015
13. Binhardi BA, Teixeira CRS, Almeida-Pititto B, Barbosa-Junior F, Franco LJ, Melo KFS et al. Diabetes self-care practices and resilience in the Brazilian COVID-19 pandemic: results of a web survey: DIABETESvid. Diabetol Metab Syndr. 2021; 19;13(1):87. https://doi.org/10.1186/s13098-021-00706-8
14. Rodrigues FFL, Santos MA, Teixeira CRS, Gonela JT, Zanetti ML. Relação entre conhecimento, atitude, escolaridade e tempo de doença em indivíduos com diabetes mellitus. Acta Paul Enferm. 2012;25(2):284-90. https://doi.org/10.1590/S0103- 2100201200020002021002012000200020.
15. Almeida-Pititto B, Dias ML, Moura FF, Lamounier R, Vencio S, Calliari LE. Metas no tratamento do diabetes. Diretriz Oficial da Sociedade Brasileira de Diabetes (2022). https://doi.org/10.29327/557753.2022-3.
16. Leitão VBG, Francisco PMSB, Malta DC, Costa KS. Tendência do uso e fontes de obtenção de antidiabéticos orais para tratamento de diabetes no Brasil de 2012 a 2018: análise do inquérito Vigitel. Rev Bras Epidemio. 2021; 24: E210008. https:// doi.org/10.1590/1980-549720210008
17. Matta SR, Bertoldi AD, Emmerick ICM, Fontanella AT, Costa KS, Luiza VL. Fontes de obtenção de medicamentos por pacientes diagnosticados com doenças crônicas, usuários do Sistema Único de Saúde. Cad. Saúde Pública. 2018; 34(3):e00073817. https://doi.org/10.1590/0102-311X00073817
18. Costa KS, Tavares NUL, Mengue SS, Pereira MA, Malta DC, Silva Júnior, JBD. Obtenção de medicamentos para hipertensão e diabetes no Programa Farmácia Popular do Brasil: resultados da Pesquisa Nacional de Saúde, 2013. Epidemiol. Serv. Saude. 2016;25(1):33-44. https://doi.org/10.5123/S1679-49742016000100004
19. Beran D, Perone SA, Perolini MC, Chappuis F, Chopard P, Haller DM et al. Beyond the virus: Ensuring continuity of care for people with diabetes during COVID-19. Prim Care Diabetes, 2021;15(1):16-17. https://doi.org/10.1016/j.pcd.2020.05.014
20. Departamento de Assistência Farmacêutica e Insumos Estratégicos (Brasil). Relação Nacional de Medicamentos Essenciais: Rename 2020 [recurso eletrônico]. Ministério da Saúde, Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde. Brasília: Ministério da Saúde 2020 acesso em 23 set 2021. Disponível em: <http://conitec.gov.br/images/Rename- 2020-final.pdf>
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 CCBY Creative Commons
This work is licensed under a Creative Commons Attribution 4.0 International License.
